Corporate Presentation December 2017
|
|
- Patrick Manning
- 6 years ago
- Views:
Transcription
1 Enhancing Life Through Nature TSX: CZO Corporate Presentation December
2 2 Forward Looking Statements This presentation contains forward-looking statements. Various factors could cause actual results to differ materially from those projected in forwardlooking statements, including those predicting the timing of product development and launches. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company s expectations are correct. All forward-looking statements are expressly qualified by this Cautionary Statement.
3 Key Management and Board Key Management Gilles Gagnon, M.Sc., MBA President and Chief Executive Officer - Over 30 years of experience in the pharmaceutical industry where he participated in launching multiple new pharmaceutical products - Former CEO of AEterna Zentaris and Vice President, External Affairs, for Novartis Pharma Canada Inc. Stacy Prefontaine, CA Chief Financial Officer - Almost 20 years of global finance and accounting experience in public company external financial reporting, corporate tax compliance and planning, and accounting practices and controls - Former Principal at Grant Thornton LLP and Partner at Stout & Company LLP Jean-Guy Boulet General Manager, Juvente DC - Over 30 years of experience in strategic marketing, marketing intelligence and growth strategy - Successful track record of launching and implementing strategic growth initiatives in international markets - Founder of Juvente DC Glenn R. Rourke, MBA - Chair of the Board - Retired Senior Vice President/Managing Director, BMO Financial Group Gilles Gagnon M.Sc., MBA - President and Chief Executive Officer Ulrich Kosciessa, Ph.D. - Member of the Executive Management Board of Medac GmbH, Managing Director of Medac International, and Chairman of the Board of Medac Pharma Inc. William W. Li, M.D. - President, Medical Director and Co-founder of the Angiogenesis Foundation Don Oborowsky - President and owner of Waiward Capital John Zupancic Board of Directors - Retired Manager of Supply and Technical Services for the Strathcona Refinery 3
4 Corporate Overview Focused on the development and commercialization of active ingredients for healthcare and cosmetic industries leveraging proprietary delivery systems Industry leading extraction manufacturing processes produce high value active ingredients from natural plant based sources Two value driving active ingredients used in multiple household name cosmetics and personal care products: beta glucan and avenanthramides Revenue generating, de-risked business model supports near-term and future growth - Strengthen and expand revenue generating base business - Imminent pivot into Biopharmaceutical company through expansion into high-growth markets Recent acquisition of Juvente DC marks important step in strategic market diversification business plan - New anti-aging skin care product line represents opportunity in a $5B market and utilizes beta glucan and avenanthramides 2016 represented highest full year revenue and operating cash flow in Company s history and set the stage for transition into nutraceutical sector 4
5 5 Diversified Business Model Expected to Drive Growth Revenue Generating Base Business Multiple Growth Opportunities Cosmeceuticals Nutraceuticals Enabling Technologies
6 6 Unique Bioprocessing Expertise Identification, extraction and purification of active compounds from natural sources Create innovative ingredients for the personal care and healthcare industries Two value driving bioactives at core of base business in cosmeceuticals - Beta glucan - Avenanthramides
7 7 Beta Glucan Water soluble fibre found in the cell walls of oat kernels Highly effective in stimulating collagen synthesis Key Benefits: - Skin restructuring and wound healing - Replenishes and protects the skin s moisture barrier - Proven to effectively reduce fine lines and wrinkles, decreasing the visible signs of aging - Linked to cholesterol reduction and/or reduced risk of heart disease Ceapro was first to demonstrate that beta glucan can be used as a delivery system
8 8 Avenanthramides Group of polyphenol compounds found exclusively in oats Antihistamine and anti-inflammatory properties - Provides relief for a host of skin conditions, such as eczema, chicken pox and insect bites Potential benefits in the control of inflammation-based diseases Ceapro is the only company in the world producing the only commercial natural avenanthramide product
9 9 Avenanthramides Clinically Proven in Cosmeceuticals Significant improvements in erythema symptoms associated in subjects with mild to moderate atopic dermatitis - 40% improvement in itch perception after 1 week - 62% of patients showed an improvement in their skin condition Subjects with atopy - 89% of subjects saw significant improvement in itch after 1 week - Continued improvement after 4 weeks
10 10 Base Business: Cosmeceuticals From Field to Formulation Revenue generating base business in personal care cosmetic market Consistent growth of at least 20% year-over-year growth Strategy focused on strengthening and expanding business by continuing to explore and clinically validate new product applications Recently renewed a major distribution agreement with long-time partner, Symrise AG
11 11 Beta Glucan and Avenanthramides in Multiple Household Name Products Aveeno Jergens Coppertone Dove Lubriderm 3M Nexcare KY Products Neutrogena Burt s Bees The Body Shop Philosophy ROC
12 12 Juvente DC - Proprietary Line of Cosmeceutical Products Acquisition of Juvente DC in October 2017 marks important step in strategic market diversification business plan Represents opportunity in a $5B market Utilizes two value driving active ingredients beta glucan and avenanthramides Anti-aging skin care product line: - Parfaite: a new generation anti-aging day cream - Absolue: an anti-aging night cream - Radieuse: an anti-aging eye contour care
13 13 Multiple High Value Growth Opportunities Cosmeceuticals Nutraceuticals Enabling Technologies
14 14 Fueling Our Nutraceuticals Pipeline From Plant to Pill Functional Drink Cholesterol Exercised Induced Inflammation
15 15 Beta Glucan: Functional Drink - Energy Booster Collaborating with the University of Alberta to develop a functional drink Impregnated beta glucan, as a delivery system, with the well-known co-enzyme Q10 as an energy booster Demonstrated first water soluble formulation of co-enzyme Q10 utilizing PGX technology Highlights: Positive results from first development phase presented at Lisbon Conference on Supercritical Fluids in April 2017 and a manuscript is being submitted for scientific publication Pure PGX BG ibg: 5.5% CoQ10 on BG
16 16 Beta Glucan: Cholesterol Reducer Oat Beta Glucan Linked to Cholesterol Reduction and/or Reduced Risk of Heart Disease Planning pilot clinical study to evaluate the efficacy of beta glucan as a cholesterol reducer The month placebo controlled study will enroll a minimum of 240 patients who cannot tolerate high doses of current treatments Additional biomarkers will also be evaluated for potential effect on insulin metabolism and other symptoms related to metabolic syndrome
17 17 Avenanthramides: Exercise-Induced Inflammation Collaborating with the University of Michigan to develop a functional food to alleviate exercise-induced inflammation Results from bioavailability study demonstrated a significant reduction of inflammation biomarkers in the blood Ongoing bio-efficacy study using low and high doses of avenanthramides as a food additive results from the study are expected in H2 2017
18 18 Potential For Multiple Value-Driving Opportunities Pressurized Gas Expanded (PGX) Liquid Spray Drying Novel spray drying technique for processing water-soluble biopolymers Platform that can produce numerous morphologies of biopolymers ranging from fine fibers to granular powder, which are highly water soluble Proprietary Enabling Technologies Extraction Fractionation Ethanol based extraction manufacturing technology Semi-continuous processes offer the ability to produce commercial scale quantities Proprietary Drying Technology Developed to produce pharma grade tablet of phenolic based compounds Ability to produce commercial scale quantities
19 19 Enabling Technologies have Broad Utility
20 20 Pressurized Gas expansion Technology (PGX) PGX is poised to be a delivery system platform Successfully completed impregnation of bioactive using PGX Technology for improved characteristics Pilot Scale Facility completed and custom designed equipment installed - Proprietary equipment will enable production of sufficient material for both development studies and sale-able product for niche applications Agreement with University of Alberta to conduct impregnation studies using PGX technology - Grant of $332K obtained from Canadian Government
21 New Bio-Processing Facility R&D Pilot Scale Capability Commercial Production New 30,000 sq. ft. GMP Bioprocessing Extraction Facility in Edmonton, Alberta, Canada 21
22 22 Financial Profile 2016 Represented Highest Full Year Revenue and Operating Cash Flow in Company s History TSX-V: CZO Stock Ticker $43M Market capitalization as of December 4, M Common shares outstanding $13,674,000 Total sales for the full year 2016
23 23 Financial Performance At Least 20% of Consistent Year-Over-Year Growth Sales, ($M) Income (loss) from operations, ($M)
24 24 Future Growth Marked by Potential to Address Significant Market Opportunities Cosmetic Injectables $686M Functional Food $240B Cosmetic Skincare $5B Antiinflammatory $57.8B Diabetes Tx $21.4B Functional Drink $17B
25 25 Investment Highlights Revenue generating, de-risked business model supports near-term and future growth Strategy focused on strengthening base cosmeceuticals business and expanding into multiple growth markets Two value driving active ingredients used in multiple household name cosmetics and personal care products Acquisition of Juvente DC represents an opportunity for vertical integration that enables our entry into a high-end market valued at $5 billion Pivoting into Biopharmaceutical company with multiple near-term value-driving opportunities expected to unlock significant shareholder value
26 Enhancing Life Through Nature TSX: CZO Corporate Presentation
Corporate Presentation September 2017
Enhancing Life Through Nature TSX: CZO Corporate Presentation September 2017 www.ceapro.com 2 Forward Looking Statements This presentation contains forward-looking statements. Various factors could cause
More informationEnhancing Life Through Nature
Enhancing Life Through Nature TSX: CZO Corporate Presentation March 2018 www.ceapro.com 2 Forward Looking Statements This presentation contains forward-looking statements. Various factors could cause actual
More informationCeapro s Journey Diversifying our Business Model
Enhancing Life Through Nature Ceapro s Journey Diversifying our Business Model Gilles R. Gagnon, M.Sc., MBA, ICD.D President and CEO TSX: CZO Annual General and Special Meeting of Shareholders May 29,
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationOWC PHARMACEUTICALS RESEARCH OTCQB:OWCP
OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationE N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE
I N V E S T O R P R E S E N TAT I O N Q 4 2 0 1 6 TM HEALTH THERAPEUTICS E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE T S X. V: E M H DISCLAIMER THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationAMERICAN ROOTS. GLOBAL REACH CSE: TGIF FWB: 1QF OTC: TGIFF
AMERICAN ROOTS. GLOBAL REACH 1 Friday Night Inc. is focused on strengthening and expanding its current cannabis operations and consultancy, and is positioning itself to thrive in the rapidly evolving cannabis
More informationInnovator Case Studies: Oncology Networks
Innovator Case Studies: Oncology Networks J. Ike Nicoll Chief Executive Officer Cancer Clinics of Excellence Alan Armer, Ph.D. Vice President, Research & Development Catholic Health Initiatives Cancer
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationOragenics Shareholder Update
January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationBioxyne Launches New Zealand Dairy Formula Product in South East Asia
Suite 506, Level 5, 50 Clarence St Sydney NSW 2000 P: +61 2 9078 8180 W: www.bioxyne.com ASX RELEASE 7 December 2017 Bioxyne Launches New Zealand Dairy Formula Product in South East Asia Highlights Bioxyne
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationFor personal use only
28 May 2015 PYL AND MMJ ON TRACK FOR REVENUES IN JULY Highlights: Production of MMJ s GMP-produced CBD food supplement capsules commenced 25 May 2015 Capsules to be branded and sold as Sativol TM Sativol
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationBoehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider
Boehringer Ingelheim Biopharmaceuticals in China Your Reliable Contract Manufacturing Solution Provider Dr. Bin Wang, Dr. Axel Schleyer Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. Contact:
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF Corporate Presentation June 2018 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com FORWARD LOOKING STATEMENTS Certain statements contained in this
More informationOWC PHARMACEUTICAL RESEARCH OTCQB:OWCP
OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationCastle Creek Pharmaceuticals
Castle Creek Pharmaceuticals Dermatology Summit Entrepreneurial Showcase 2018 Michael Derby, CEO January 7, 2018 Castle Creek Pharma Driving innovation in dermatology We are a high-growth biotech company
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationReady for a Fundraising Breakthrough?
Ready for a Fundraising Breakthrough? Fundraising never looked so good. Although I have formulated thousands of products during my 40+ years in the skincare manufacturing industry, I have never seen a
More informationCase 2:09-cv FSH-PS Document 1-3 Filed 08/24/2009 Page 1 of 5. Exhibit B
Case 2:09-cv-04329-FSH-PS Document 1-3 Filed 08/24/2009 Page 1 of 5 Exhibit B Case 2:09-cv-04329-FSH-PS Document 1-3 Filed 08/24/2009 Page 2 of 5 TO OUR FELLOW SHAREHOLDERS: In 2001 we made significant
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationCOMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing
COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.
More informationMEDICAL CANNABIS COMPANY
MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward looking statements
More informationGENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE
GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S.
More informationLetter from the CEO. Dear Friends of IAVI,
IAVI Annual Report 2017 Letter from the CEO Dear Friends of IAVI, We are pleased to present an overview of the progress IAVI and partners have made in 2017 toward our pursuit of the development of vaccines
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationBuilding a Global Neurotoxin Franchise
JUNE 2, 2014 Building a Global Neurotoxin Franchise DAN BROWNE President & CEO Forward-Looking Statements This presentation contains forward-looking statements, including statements related to the process
More informationUpdate on emollients
Update on emollients Amal Mhanna, MD Pediatric Dermatologist Clemenceau Medical Center Disclosure: I was a member of an advisory board y for J&J and received honoraria. Emollients and moisturizers are
More informationWelcome to Galenicum! APRIL, 2013
Welcome to Galenicum! APRIL, 2013 Our corporate image comes from the sunrise. Night represents disease, daylight means health and the sunrise stands for overcoming GALENICUM CORPORATE PRESENTATION 3 Who
More informationWE VE GOT THE POWDER THE KEY TO YOUR NEW MEDICATED CHEWING GUM
WE VE GOT THE POWDER THE KEY TO YOUR NEW MEDICATED CHEWING GUM Health in Gum is a powdered excipient specially designed to formulate and produce medicated chewing gum It combines gum base and sweeteners
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationCommitted to Conquering Heart Failure
Committed to Conquering Heart Failure January 2018 Cardiol is focused on the research and development of nanotherapeutics for the treatment of heart failure and other inflammatory conditions. Market Opportunity
More informationFor personal use only
13 February 2018 Creso reports strong progress with construction of its Canadian medicinal cannabis production facility in Nova Scotia Highlights: Site works at Creso s Canadian medicinal cannabis production
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationLeader in custom manufacturing. for the pharmaceutical and nutraceutical industries.
Leader in custom manufacturing for the pharmaceutical and nutraceutical industries. Since its inception in April 1994, Viva Pharmaceutical Inc. has built a reputation as a leading manufacturer committed
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationFor personal use only
AusCann Makes Major Progress Towards Production of Cannabinoid Medicines During FY18 Highlights Undertook comprehensive pharmaceutical development project to create an optimal dosage form cannabinoid medicine
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationDSM Capital Markets Day 2018
DSM Capital Markets Day 2018 Human Nutrition & Health Jeremy Xu President Human Nutrition & Health ROYAL DSM CAPITAL MARKETS DAY LONDON (UK) 20 JUNE 2018 Safe harbor statement This presentation may contain
More informationextracts from India The World Health Organization (WHO) estimates 4 billion people use herbal medicine.
World Class Botanicals extracts from India Presented by: Madhu.K Team Leader International Business Remedies Pvt Lts Bangalore madhu@naturalremedy.com, www.naturalremedycom Remedies Solutions for Healthy
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationH. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationInvestor Presentation
Investor Presentation Spring 2019 OTCQX:MDCL www.medicinemantechnologies.com SAFE HARBOR STATEMENT: This presentation may contain forward looking statements which are based on current expectations, forecasts,
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION JUNE 2016 OTCQB:CANN ABOUT General Cannabis Corporation (GCC) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationInvestor Presentation September Cogstate Ltd. All rights reserved.
Investor Presentation September 2017 2017 Cogstate Ltd. All rights reserved. We believe that brain health is profoundly important to quality of life and should be easier to measure. That s why we so passionately
More informationPurolite Life Sciences Brand Positioning Catalyst
Purolite Life Sciences Brand Positioning Catalyst Presenting Brand Therapy Perceptions Goals Admired Brands Brand Narrative Brand Legacy Brand Story Vision, Mission, Promise Primary Messaging Brand Therapy
More informationCochlear Limited 2017 Annual General Meeting Chairman s Address
Cochlear Limited 2017 Annual General Meeting Chairman s Address 17 October 2017 Rick Holliday-Smith Chairman Ladies and gentlemen Financial results Cochlear reported a record net profit of $224 million,
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationIntroductory Presentation
Introductory Presentation WEEK 6 WEEK WEEK 1 2 WEEK 5 WEEK 3-4 STRUCTURED HORIZON WELCOME TO THE FAMILY FRANCHISE AGREEMENT DELIVERY PERSONALIZED FRANCHISE AGREEMENTS DELIVERED DAY OF DISCOVERY MEET THE
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationCreating Value from Natural Actives Extraction. November 2016
Creating Value from Natural Actives Extraction November 2016 Disclaimer The information contained in this presentation is provided by Radient Technologies Inc. ( Radient ) for informational purposes only
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationAXIM Biotechnologies Reports Year End 2017 Results
March 19, 2018 AXIM Biotechnologies Reports Year End 2017 Results NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationThe Opportunities for Oats in Cosmetics. Cark Maunsell
The Opportunities for Oats in Cosmetics Cark Maunsell Oat Services Ltd Oat Cosmetics is the marketing Brand for Oat Services Ltd Oat Services Ltd: Suppliers oat blends to a major bakery chain Import logistics
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationTIME IS THE KEY IN CANCER DIAGNOSTICS. THIS IS WHY WE HAVE CREATED INPROBE MINIMALLY INVASIVE MEDICAL DEVICE CAPABLE OF REAL-TIME DIAGNOSTICS OF HER2
TIME IS THE KEY IN CANCER DIAGNOSTICS. THIS IS WHY WE HAVE CREATED INPROBE MINIMALLY INVASIVE MEDICAL DEVICE CAPABLE OF REAL-TIME DIAGNOSTICS OF HER2 BREAST CANCER AND HER2 STOMACH CANCER BIOMARKERS. GLOBAL
More informationMinistry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW
Chapter 1 Section 1.08 Ministry of Health and Long-Term Care Palliative Care Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW # of Status of Actions Recommended Actions
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationNovan Announces Promising Clinical Results with SB414
Novan Announces Promising Clinical Results with SB414 In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant
More informationManagement Presentation. June 2017
Management Presentation June 2017 Forward Looking Statements The statements made in this presentation may include forward-looking statements regarding the treatment of orthopoxvirus infections, the development
More informationCERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery
Press release CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery Combining LYPRO Biosciences NanoDisk technology with CERENIS
More informationGENETIC TECHNOLOGIES LIMITED
GENETIC TECHNOLOGIES LIMITED A.B.N. 17 009 212 328 Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 March 2018 Quarterly Activities Report for the quarter ended
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationPipeline Preclinical Phase 1 Phase 2 Phase 3 BLA/NDA/MAA BIOMARIN:MATCHING PROVEN SCIENCE WITH PROVEN NEEDS
Pipeline Preclinical Phase 1 Phase 2 Phase 3 BLA/NDA/MAA On The Market Naglazyme for MPS VI Aldurazyme for MPS I Orapred ODT for Inflammatory Conditions Phenoptin for PKU 6R-BH4 for Cardiovascular Indications
More informationNestlé Investor Seminar 2008
Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationChronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA
Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA US Chronic Care has outperformed the market by a factor 2-3x and continues
More informationPROFOUND MEDICAL CORP.
PROFOUND MEDICAL CORP. Pioneering a new standard of care in the treatment of prostate cancer Forward-Looking Statements This presentation and oral statements made during this meeting regarding Profound
More informationAnnual General Meeting 25 October Cogstate Ltd. All rights reserved.
Annual General Meeting 25 October 2017 2017 Cogstate Ltd. All rights reserved. Board of Directors Audit, Risk & Compliance Committee Remuneration & Nomination Committee Martyn Myer Non-Exec Chairman Yes
More informationContinued value growth
Continued value growth Leendert Staal CEO & President DSM Nutritional Products Capital Markets Days 2012 Safe harbor statement This presentation may contain forward-looking statements with respect to DSM
More informationwww. isotopeworld.com Advanced Medical Isotope Corporation
www. isotopeworld.com Advanced Medical Isotope Corporation www. isotopeworld.com James C. Katzaroff Founder, CEO, Chairman December 5, 2016 Safe Harbor Statement This Overview contains forward-looking
More informationSPY Imaging for Surgeons
SPY Imaging for Surgeons Forward-Looking Statements These slides accompany an oral presentation by Novadaq Technologies, Inc., which contains forwardlooking statements. Actual results may differ materially
More informationThe power of innovation to save lives
Innovative Finance The power of innovation to save lives May 2013 The challenge Life or death for a young child too often depends on whether he is born in a country where vaccines are available or not.
More informationCompany Overview. Jefferies 2016 Healthcare Conference June 9 th, 2016
Company Overview Jefferies 2016 Healthcare Conference June 9 th, 2016 1 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical
More informationNutritional Products & Wellness Solutions. Your Source of Excellence
Nutritional Products & Wellness Solutions Your Source of Excellence Company Neptune was founded in 1998 and pioneered the krill oil industry with the launch of our flagship product, Neptune Krill Oil
More informationManagement Presentation. January 2019
Management Presentation January 2019 Forward Looking Statements The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirusinfections,
More information